SpringWorks Therapeutics, Inc. (SWTX) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2025-07-01

SpringWorks Therapeutics, Inc. (SWTX) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every SWTX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About SpringWorks Therapeutics, Inc. (SWTX)

SEC CIK	0001773427

Recent SWTX Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-07-01	LYNCH DANIEL	Director	D — Derivative transaction	93.0K	—	—	SEC
2025-07-01	Fuhrman Alan	Director	D — Derivative transaction	24.7K	—	—	SEC
2025-07-01	Perier Francis I Jr	Chief Financial Officer	D — Derivative transaction	60.9K	—	—	SEC
2025-07-01	Weinstein Herschel S	General Counsel Secretary	D — Derivative transaction	55.2K	—	—	SEC
2025-07-01	MACKAY MARTIN	Director	D — Derivative transaction	20.0K	—	—	SEC
2025-07-01	Lewis-Hall Freda C	Director	D — Derivative transaction	24.7K	—	—	SEC
2025-07-01	ALBAN CARLOS	Director	D — Derivative transaction	28.9K	—	—	SEC
2025-07-01	Islam Saqib	Chief Executive Officer	D — Derivative transaction	954.9K	—	—	SEC
2025-07-01	Hambleton Julie	Director	D — Derivative transaction	14.2K	—	—	SEC
2025-07-01	Nofi Michael	Chief Accounting Officer	D — Derivative transaction	30.6K	—	—	SEC
2025-07-01	Ashar Bhavesh	Chief Commercial Officer	D — Derivative transaction	62.1K	—	—	SEC
2025-07-01	Lin Tai-An	Chief Scientific Officer	D — Derivative transaction	33.0K	—	—	SEC
2025-07-01	Pichl Daniel	Chief People Officer	D — Derivative transaction	50.8K	—	—	SEC
2025-07-01	Edris Badreddin	Chief Operating Officer	D — Derivative transaction	169.7K	—	—	SEC
2025-07-01	Cassidy James	Chief Medical Officer	D — Derivative transaction	81.7K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for SpringWorks Therapeutics, Inc. (SWTX). Updated in real time as new filings are submitted to the SEC.

Recent Insider Filings

2025-07-01 — Fuhrman Alan (Director)
2025-07-01 — Perier Francis I Jr (Chief Financial Officer)
2025-07-01 — Weinstein Herschel S (General Counsel Secretary)
2025-07-01 — MACKAY MARTIN (Director)
2025-07-01 — LYNCH DANIEL (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SWTX insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

SWTX Insider Trading — FAQ

What is the latest insider trade for SWTX?: SpringWorks Therapeutics, Inc. (SWTX) had 0 insider filings in the last 90 days, with the most recent on 2025-07-01. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying SWTX stock?: 0 insider purchases of SWTX were filed in the last 90 days.
How many insiders are selling SWTX stock?: 0 insider sales of SWTX were filed in the last 90 days.
Where can I see SWTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every SWTX SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live SWTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.